NAS10031,281+0.66%S&P7,828+0.70%GOLD$4,184+0.66%BTC$85,601−0.22%VIX15.03−3.16%live tape · as of 17:01 UTC
The Screen
NewAmsterdam Pharma Company N.V.
NAMSW · Nasdaq · USD · 100 employees
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.
FAIL · Does not pass the screen
11.49 USD
Screen close, 2026-09-18 · not a live quote Last reviewed 18 days ago
Screened 2026-09-18 · the tape above runs as of 17:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 11.49 against the desk's fair-value range, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price11.49 USD
Ethical score70.0/100
Our investment reviews on this name
2026-08-06Read Markdown20.56-44.1% to today ✓
2026-07-02Read Markup18.80-38.9% to today
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
NewAmsterdam Pharma Company N.V. holds its Markdown at $11.49. Consolidating, no directional conviction, held for 3 days.
As held on the ledger · 2026-09-18
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 3 days
Price at the screen
$11.49
Valuation
N/A trailing · N/A forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.08
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.03%
Below 33%
Interest-bearing debt is just 0.0% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
12.04%
Below 33%
Cash held in interest-bearing accounts and securities is 12.0% of assets, under the one-third limit.
Pass
Receivables
66.71%
Below 49%
Money owed to the company is 66.7% of assets, above the 49% limit.
Fail
Revenue purity
100.00%
Below 5%
100.0% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
NewAmsterdam Pharma's business is fine, but its receivables are about 67% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
The risks · The things to watch: its business and earnings are exposed to Netherlands and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
NAMSW trades on Nasdaq (the company is based in Netherlands). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Markdown$11.49-44.1%Entry 6
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 44.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 101%. Our forward projection puts the odds of a 10% gain over the next month near 38%.
2026-09-06Markdown$20.56+0.0%Entry 5
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 101%. Our forward projection puts the odds of a 10% gain over the next month near 38%.
2026-08-06Markdown · changed$20.56+9.4%Entry 4
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 9.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 101%. Our forward projection puts the odds of a 10% gain over the next month near 38%.
2026-07-18Markup$18.80+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 101%. Our forward projection puts the odds of a 10% gain over the next month near 38%.
2026-07-03Markup$18.80+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markup$18.80Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$28.00
-33.6%
·
$664
-33.6%
2 months
$23.40
-20.5%
·
$795
-20.5%
3 months
$18.45
+0.8%
·
$1,008
+0.8%
6 months
$24.09
-22.8%
·
$772
-22.8%
1 year
$9.26
+100.9%
·
$2,009
+100.9%
2 years
$8.40
+121.4%
·
$2,214
+121.4%
3 years
$1.92
+868.8%
·
$9,688
+868.8%
5 years
$1.01
+1,741.6%
·
$18,416
+1,741.6%
Historical returns from market close data. Past performance does not guarantee future results.
The Ledger's Promise
This entry now belongs to the ledger. Whatever NAMSW does next, these words stay.
NewAmsterdam Pharma Company N.V. · NAMSW · Markdown · $11.49
Recorded 2026-09-18 · before the outcome · scored mechanically